Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.

Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. J Immunother. 2022 06 01; 45(5):254-262.

View in: PubMed

subject areas

Antigens, CD19
Biological Products
HIV Infections
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse
Neoplasms, Second Primary
Retrospective Studies

authors with profiles

Koen Van Besien